Default company panoramic image
Logo

MediBeacon LLC

MediBeacon’s System will be a real-time, accurate, cost-effective, non-radioactive and easy to use monitor of kidney function.

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location St. Louis, MO, USA
  • Currency USD
  • Founded March 2012
  • Employees 3
  • Website medibeacon.com

Company Summary

MediBeacon, founded on assets and IP acquired from Covidien, focuses on commercialization of agents for physiological monitoring, surgical guidance and imaging of pathological disease. MediBeacon's first product will be a critical tool for nephrologists, intensivists, and radiologists along with many others who need accurate and real-time assessment of the kidneys for dynamic patients. The market potential is estimated at $2 billion.

Team

  • Default avatar
    Steven J Hanley
    Chief Executive Officer

    Mr. Hanley spent 18 years at the Covidien family of companies and is the former President of Covidien’s Imaging Solutions business unit with annual global revenue exceeding $1.2 billion. He led a multifunctional organization that included sales, marketing, logistics, manufacturing, as well as research and development. Mr. Hanley is Principal and Founder of Neem LLC which focuses on entrepreneurial medical device and life science companies.

  • Default avatar
    Richard B Dorshow
    Chief Scientific Officer

    Dr. Dorshow PhD is a research physicist and manager with over 25 years in R&D. He established and led the optical diagnostics and therapeutics program at Mallinckrodtand subsequently Covidien. He constructed its Intellectual Property position, and is co-inventor on over 60 issues US patents. Dr. Dorshow has authored over 40 technical articles in this field. Dr Dorshow will lead the R & D, clinical and regulatory efforts at MediBeacon.

  • Default avatar
    Terence H Stern
    Vice President of Business Development

    Mr. Stern is a multi-lingual, global executive with a record of entrepreneurial achievement in the life sciences. As CEO and Founder of Vetbrands International he led the private equity backed buyout of Ralston Purina’s pharmaceutical business in 2002 culminating in the sale of this Brazilian business to Ceva Santé Animale in 2007. Mr. Stern held various management and development roles at Novus before joining Neem as Practice Lead in 2011.

Advisors

  • Default avatar
    Andy Hoyne
    Lawyer
    Unconfirmed

Previous Investors

  • Default avatar
    St Louis Biogenerator
    Unconfirmed
    Default avatar
    Missouri Technology Corporation
    Unconfirmed
    Default avatar
    St Louis Development Corporation
    Unconfirmed